Ovarian Cancer News & Features

BRCA Carriers Have Improved Survival in Ovarian Cancer

January 25, 2012

For patients with invasive epithelial ovarian cancer (EOC), BRCA1 and BRCA2 mutations are associated with improved five-year survival, according to a study.
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

Genetic variation in ovarian cancer thwarts treatment

Delicia Honen Yard December 27, 2011

Women with a variant of the KRAS oncogene are three times more resistant to platinum chemotherapy, the standard treatment for ovarian cancer, than are women without this variant.
 

Fluorescence-guided surgery puts ovarian cancer in a new light

Delicia Honen Yard October 19, 2011

A surgical method employing fluorescent imaging agents can help surgeons remove malignant tissue that otherwise might have been missed in women with ovarian cancer.
 

PARP inhibitor found effective in women without BRCA mutation

October 18, 2011

A poly(ADP-ribose) polymerase (PARP) inhibitor that has shown promising anticancer activity in the presence of BRCA1 or BRCA2 gene mutations also appears to be effective in the treatment of more common, nonhereditary ovarian tumors.
 

Costly clots common in cancer

Delicia Honen Yard October 18, 2011

As many as 1 in 5 people risk developing a venous thromboembolism (VTE) within a year after undergoing treatment for some types of cancers, researchers reported.
 

Risk factors identified for postop mortality in advanced ovarian cancer

Delicia Honen Yard September 12, 2011

Advancing age, increasing stage, and increasing comorbidity score were all associated with an increase in 30-day mortality among women who had surgery for advanced ovarian cancer.
 

Basic steps are best bet for detecting gynecologic cancer recurrence

Delicia Honen Yard June 17, 2011

The best approach for detecting most gynecologic cancer recurrences is to take a thorough history, perform a thorough examination, and educate the patient about concerning symptoms.
 

Celecoxib may be new weapon in fight against liver cancer

Delicia Honen Yard June 06, 2011

A cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug (NSAID) usually prescribed to relieve arthritis pain appears to be an effective treatment for liver cancer.
 

PARP inhibitors may benefit patients with colorectal cancer

Delicia Honen Yard May 09, 2011

Colorectal tumors with mutations in the MRE11 gene may be vulnerable to PARP inhibitors, a class of drugs that has already demonstrated safety in early clinical trials of breast and ovarian cancers.
 

Ovarian Cancer Clinical Trials

Clinical Trial: Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

Clinical Trial: Data Collection for Patients With Low Grade Ovarian Carcinoma

Clinical Trial: Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer

Clinical Trial: Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Clinical Trial: Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions